...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.
【24h】

Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.

机译:在心力衰竭大鼠模型中的肌浆网C​​a(2 +)-ATPase基因转移后存活和心脏代谢的改善。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: In heart failure, sarcoplasmic reticulum (SR) Ca(2+)-ATPase (SERCA2a) activity is decreased, resulting in abnormal calcium handling and contractile dysfunction. We have previously shown that increasing SERCA2a expression by gene transfer improves ventricular function in a rat model of heart failure created by ascending aortic constriction. METHODS AND RESULTS: In this study, we tested the effects of gene transfer of SERCA2a on survival, left ventricular (LV) volumes, and metabolism. By 26 to 27 weeks after aortic banding, all animals developed heart failure (as documented by >25% decrease in fractional shortening) and were randomized to receive either an adenovirus carrying the SERCA2a gene (Ad.SERCA2a) or control virus (Ad.betagal-GFP) by use of a catheter-based technique. Sham-operated rats, uninfected or infected with either Ad.betagal-GFP or Ad.SERCA2a, served as controls. Four weeks after gene transfer, survival in rats with heart failure treated with Ad.betagal-GFP was 9%, compared with 63% in rats receiving Ad.SERCA2a. LV volumes were significantly increased in heart failure (0.64+/-0.05 versus 0.35+/-0.03 mL, P<0.02). Overexpression of SERCA2a normalized LV volumes (0.46+/-0.07 mL) in the failing hearts. (31)P NMR analysis showed a reduced ratio of phosphocreatine to ATP content in failing+Ad.betagal-GFP compared with sham+Ad.betagal-GFP (0.82+/-0.13 versus 1.38+/-0.14, P<0.01). Overexpression of SERCA2a in failing hearts improved the phosphocreatine/ATP ratio (1.23+/-0.28). CONCLUSIONS: In this study, we show that unlike inotropic agents that improve contractile function at the expense of increased mortality and worsening metabolism, gene transfer of SERCA2a improves survival and the energy potential in failing hearts.
机译:背景:在心力衰竭中,肌浆网(SR)Ca(2 +)-ATPase(SERCA2a)活性降低,导致异常的钙处理和收缩功能障碍。我们先前已经表明,通过基因转移增加SERCA2a表达可改善由升主动脉缩窄所致的心力衰竭大鼠模型的心室功能。方法和结果:在这项研究中,我们测试了SERCA2a基因转移对生存,左心室(LV)体积和代谢的影响。在主动脉束带后第26至27周,所有动物均出现心力衰竭(如缩短分数减少> 25%所记录),并被随机分配接受带有SERCA2a基因(Ad.SERCA2a)的腺病毒或对照病毒(Ad.betagal -GFP)通过使用基于导管的技术。未感染或未感染Ad.betagal-GFP或Ad.SERCA2a的假手术大鼠作为对照。基因转移后四周,接受Ad.betagal-GFP治疗的心力衰竭大鼠的存活率为9%,而接受Ad.SERCA2a的大鼠为63%。心力衰竭患者的左室容量明显增加(0.64 +/- 0.05 mL vs 0.35 +/- 0.03 mL,P <0.02)。 SERCA2a的过表达使衰竭心脏中的LV体积标准化(0.46 +/- 0.07 mL)。 (31)P NMR分析显示,与假+ Ad.betagal-GFP相比,失败+ Ad.betagal-GFP中磷酸肌酸与ATP含量的比率降低(0.82 +/- 0.13对1.38 +/- 0.14,P <0.01)。 SERCA2a在衰竭心脏中的过表达改善了磷酸肌酸/ ATP比(1.23 +/- 0.28)。结论:在这项研究中,我们表明,与以收缩力增加死亡率和恶化新陈代谢为代价来改善收缩功能的正性肌力药物不同,SERCA2a的基因转移提高了心脏衰竭患者的生存率和能量潜能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号